A Lancet study found stopping statins after 75 did not raise deaths in low-risk seniors

A new study published in The Lancet has added evidence to one of the more fraught questions in geriatric medicine: whether older adults who have taken cholesterol-lowering statins for years can safely stop. The analysis found that discontinuing the drugs after age 75 did not raise the risk of death among healthy, low-risk seniors who had no established heart disease. The finding speaks directly to a large group of patients who have long wondered whether decades of daily pills still serve a purpose late in life.

What statins do and why they are so widely prescribed

Statins are among the most commonly prescribed medications in the world, taken by tens of millions of people to lower low-density lipoprotein, the so-called bad cholesterol that contributes to the buildup of plaque in arteries. By reducing that cholesterol, the drugs lower the risk of heart attacks and strokes, and for people who have already had a cardiac event they are considered a cornerstone of treatment. Their benefit in that group is well established and rarely in dispute.

The uncertainty has centered on primary prevention, meaning the use of statins in people who have not yet had a heart attack or stroke but take the drugs to reduce their future risk. Much of the foundational research on statins enrolled middle-aged adults, leaving the oldest patients underrepresented and their doctors to extrapolate from data that may not fit them well.

The gap in evidence for patients over 75

Guidelines have offered limited direction for people in their late seventies and beyond, in part because clinical trials have historically excluded or underrepresented the very old. That gap matters because the calculus of a preventive drug shifts with age. A medication that pays off over a decade or two may offer less clear benefit to someone whose competing health risks have changed, and the potential downsides of continued treatment loom larger.

Older adults are also more likely to experience side effects such as muscle aches and to juggle multiple prescriptions at once, raising the odds of drug interactions and complicating daily routines. Against that backdrop, clinicians and patients have lacked solid data on what happens when a long-term statin user simply stops, which is the question the new analysis set out to address.

What the Lancet analysis found

The study concluded that among healthy older adults, stopping statins after age 75 did not raise the risk of death in those considered low-risk, meaning people without established cardiovascular disease. In practical terms, the researchers found no signal that discontinuation harmed this specific group, an outcome that reframes the decision as a genuine choice rather than a one-way commitment.

The result applies to a carefully defined population and should not be read as a blanket endorsement of quitting the drugs. It addresses low-risk seniors taking statins for prevention, not people who have already suffered a heart attack or stroke, for whom the evidence supporting continued treatment remains strong. The distinction between primary and secondary prevention is central to interpreting the finding correctly.

Why deprescribing is gaining attention in older patients

The study lands amid a broader movement in medicine toward deprescribing, the deliberate practice of reviewing and, when appropriate, stopping medications that may no longer benefit a patient. As people accumulate diagnoses and prescriptions over a lifetime, their pill regimens can grow to a point where the burdens and interaction risks outweigh the advantages of any single drug. Statins, given how widely they are prescribed, are a frequent focus of that reassessment.

Deprescribing is not simply about taking fewer pills for its own sake. It reflects an effort to match treatment to a patient’s current goals, life expectancy, and tolerance for side effects rather than continuing a regimen on autopilot. Evidence that a common drug can be safely withdrawn in a defined group gives clinicians firmer ground to have that conversation.

What the finding does not say

The results carry important limits. The reassurance applies to healthy, low-risk individuals over 75 without a history of cardiovascular disease, and extending it to patients outside that description would misread the science. People taking statins after a heart attack, a stroke, or a diagnosis of coronary artery disease fall into a different category, and the case for keeping them on the drugs remains robust.

Observational and population-level findings also cannot capture every individual circumstance. Factors such as cholesterol levels, family history, other chronic conditions, and personal preferences all bear on whether continuing or stopping makes sense for a particular person. The study narrows the uncertainty for one group without resolving it for everyone who takes the medication.

How patients and doctors are likely to use the result

For clinicians, the practical value of the analysis is that it supports an individualized conversation rather than a default assumption that a statin, once started, must be taken for life. Experts consistently caution that patients should not stop any prescribed medication on their own, and that a decision to discontinue belongs in a discussion with a doctor who knows the full medical picture.

For the large number of seniors who have taken statins for years and questioned whether the daily habit still earns its place, the study offers a measure of reassurance that stopping is, for the low-risk among them, a reasonable option to weigh. The broader lesson is that preventive medicine is not static, and that periodically revisiting long-standing prescriptions is a legitimate part of caring for aging patients.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview